Viridian Therapeutics
Stock Forecast, Prediction & Price Target
Viridian Therapeutics (VRDN) stock Price Target by analysts
$40.17
Potential upside: 125.52%
Viridian Therapeutics price prediction
What is Viridian Therapeutics stock analysts` prediction?
Viridian Therapeutics stock forecast: Based on 5 Wall Street analysts` predicted price targets for Viridian Therapeutics in the last 3 months, the avarage price target is $40.17, with a high forecast of $NaN. The average price target represents a 125.52% change from the last price of $17.81.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Viridian Therapeutics stock Price Target by analysts
Full breakdown of analysts given Viridian Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Alex Thompson Stifel Nicolaus | 0% 0/2 | 10 months ago | $41 130.20% upside | $22.81 | StreetInsider | Previous targets (1) |
Gregory Renza RBC Capital | 0% 0/2 | 12 months ago | $44 147.05% upside | $20.7 | TheFly | Previous targets (1) |
Kalpit Patel B.Riley Financial | 0% 0/2 | 12 months ago | $22 23.52% upside | $19.24 | StreetInsider | Previous targets (1) |
Serge Belanger Needham | 0% 0/1 | 12 months ago | $38 113.36% upside | $19.02 | StreetInsider | Previous targets (0) |
Alex Thompson Stifel Nicolaus | 0% 0/2 | 12 months ago | $40 124.59% upside | $17.37 | TheFly | Previous targets (1) |
Julian Harrison BTIG | 0% 0/2 | 12 months ago | $56 214.43% upside | $17.27 | StreetInsider | Previous targets (1) |
Richard Law Goldman Sachs | 0% 0/2 | about 1 year ago | $25 40.37% upside | $14.18 | StreetInsider | Previous targets (1) |
Julian Harrison BTIG | 0% 0/2 | about 1 year ago | $46 158.28% upside | $12.96 | StreetInsider | Previous targets (1) |
Gregory Renza RBC Capital | 0% 0/2 | about 1 year ago | $35 96.51% upside | $12.96 | StreetInsider | Previous targets (1) |
Andy Chen Wolfe Research | 0% 0/1 | about 1 year ago | $29 62.82% upside | $12.22 | TheFly | Previous targets (0) |
Richard Law Goldman Sachs | 0% 0/2 | over 1 year ago | $23 29.14% upside | $12.34 | TheFly | Previous targets (1) |
Leland Gershell Oppenheimer | 0% 0/1 | over 1 year ago | $31 74.05% upside | $14.9 | StreetInsider | Previous targets (0) |
Douglas Tsao H.C. Wainwright | 0% 0/1 | over 1 year ago | $27 51.60% upside | $14.9 | StreetInsider | Previous targets (0) |
Kalpit Patel B.Riley Financial | 0% 0/2 | over 1 year ago | $20 12.29% upside | $14.9 | StreetInsider | Previous targets (1) |
Unknown Leerink Partners | N/A | over 2 years ago | $45 152.66% upside | $27.46 | Benzinga | N/A |
Unknown Needham | N/A | over 2 years ago | $45 152.66% upside | $27.88 | Benzinga | N/A |
Unknown Credit Suisse | N/A | over 2 years ago | $51 186.35% upside | $27.7 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | almost 3 years ago | $35 96.51% upside | $25.27 | Benzinga | N/A |
Unknown JMP Securities | N/A | almost 3 years ago | $46 158.28% upside | $21.63 | Benzinga | N/A |
Viridian Therapeutics Financial Estimates
Viridian Therapeutics Revenue Estimates
Viridian Therapeutics EBITDA Estimates
Viridian Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $2.96M N/A | $1.77M -40.19% | $314K -82.27% | Avg: $304.62K Low: $156.78K High: $447.97K avg. -2.98% | Avg: $114.58M Low: $47.29M High: $304.66M avg. 37517.09% | Avg: $457.85M Low: $188.95M High: $1.21B avg. 299.56% | Avg: $796.74M Low: $328.81M High: $2.11B avg. 74.01% |
Net Income
% change YoY
| $-79.41M N/A | $-125.44M -57.95% | $-237.73M -89.51% | Avg: $-270.46M Low: $-220.64M High: $-122.18M avg. -13.76% | Avg: $-199.33M Low: $-212.14M High: $182.15M avg. 26.30% | Avg: $25.21M Low: $5.96M High: $79.57M avg. 112.64% | Avg: $169.47M Low: $40.08M High: $534.91M avg. 572.19% |
EBITDA
% change YoY
| $-79.29M N/A | $-129.38M -63.18% | $-234.56M -81.28% | Avg: $-304.62K Low: $-447.97K High: $-156.78K avg. 99.87% | Avg: $-114.58M Low: $-304.66M High: $-47.29M avg. -37517.09% | Avg: $-457.85M Low: $-1.21B High: $-188.95M avg. -299.56% | Avg: $-796.74M Low: $-2.11B High: $-328.81M avg. -74.01% |
EPS
% change YoY
| -$6.66 N/A | -$3.91 41.29% | -$5.31 -35.80% | Avg: -$3.99 Low: -$4.93 High: -$2.73 avg. 24.87% | Avg: -$2.84 Low: -$4.74 High: $4.07 avg. 28.80% | Avg: $0.56 Low: $0.13 High: $1.78 avg. 119.83% | Avg: $3.79 Low: $0.9 High: $11.95 avg. 572.19% |
Operating Expenses
% change YoY
| $82.69M N/A | $136.07M 64.55% | $254.76M 87.22% | Avg: $21.10M Low: $10.86M High: $31.03M avg. -91.71% | Avg: $7.93B Low: $3.27B High: $21.10B avg. 37517.09% | Avg: $31.71B Low: $13.08B High: $84.32B avg. 299.56% | Avg: $55.19B Low: $22.77B High: $146.73B avg. 74.01% |
FAQ
What is Viridian Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 174.34% in 2025-2028.
We have gathered data from 11 analysts. Their low estimate is -220.64M, average is -270.46M and high is -122.18M.
What is Viridian Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 9471.92% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $156.78K, average is $304.62K and high is $447.97K.
What is Viridian Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 186.42% in 2025-2028.
We have gathered data from 11 analysts. Their low earnings per share estimate is -$4.93, average is -$3.99 and high is $-2.73.
What is the best performing analyst?
In the last twelve months 5 analysts have been covering Viridian Therapeutics stock. The most successful analyst is Alex Thompson.